Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study reports lifetime prevalence of certain "psychosomatic disorders" in psychiatric patients in India. The "psychosomatic disorders" studied were peptic ulcer, bronchial asthma, rheumatoid arthritis, ischemic heart disease and irritable bowel syndrome. One percent of psychiatric patients had these psychosomatic illnesses. Ten of the fifteen cases had two psychosomatic illnesses. Patients with psychosomatic disorders were significantly more often older in age (p = 0.003) and from an urban background (p = 0.05) as compared to other psychiatric patients. Depression was the commonest diagnosis, and was significantly (p = 0.01) more often diagnosed in the psychosomatic patients. Psychosis was not diagnosed in patients with psychosomatic disorders. This article emphasizes the need for identifying concomitant psychosomatic problems in psychiatric patients for their appropriate management.
 ...
PMID:Psychosomatic patients in a psychiatric clinic. 326 96

Quality-of-life (QOL) assessment is becoming increasingly important in the evaluation of the impact of disease and the effect of therapy. This is particularly so forirritable bowel syndrome (IBS) where there is often a tendency for a chronic clinical course, but with no associated mortality. Instruments used to study quality of life may be generic or disease specific, and care needs to be taken to ensure that the instrument used has been adequately validated for the purpose intended. Several disease-specific instruments [Irritable Bowel Syndrome Quality of Life (IBS-QOL, IBSQOL) and Functional Digestive Disorders Quality of Life (FDDQL)], in addition to generic measures, are now available for use in IBS. Quality of life in patients with IBS is surprisingly poor, particularly in the population seeking healthcare, where it can be compared with conditions which carry a high mortality, such as ischaemic heart disease, heart failure and diabetes mellitus. Pain severity appears to be an important factor in determining quality of life in IBS, although bowel disturbance and psychological difficulties are also likely to be important. There is limited data on the effect of treatment of IBS on quality of life. Improvement has been reported with dietry modification, drug treatments and hypnotherapy. It is likely that, in the future, QOL measures will become increasingly used as secondary end-points in therapeutic trials in IBS.
 ...
PMID:Quality of life in irritable bowel syndrome. 1145 12

Low residue or fiber deficient diets have been implicated in the etiology of numerous disorders, (1) from colonic neoplasms to dental caries, from varicose veins to atheroma and ischemic heart disease.(2, 3) Although wheat bran is the most commonly mentioned source of dietary fiber, there are many other sources available.What is fiber and what is its importance? Is it merely another fad? Previously irritable bowel syndrome and diverticular disease were treated with a low residue diet-has the change to a high fiber diet been justified? Only recently has methodology effectively separated crude fiber from dietary fiber. Few, and often conflicting, clinical trials are available for management guidance.
 ...
PMID:The bulk of gastroenterology. 2046 85

Many pain conditions in patients tend to co-occur, influencing the clinical expressions of each other in various ways. This paper summarizes the main concurrent pain conditions by analyzing the major interactions observed. In particular, co-occurrence will be examined in: visceral pain (especially ischemic heart disease, irritable bowel syndrome, dysmenorrhea/endometriosis and urinary pain), fibromyalgia, musculoskeletal pain and headache. Two concurrent visceral pains from internal organs sharing at least part of their central sensory projection can give rise to viscero-visceral hyperalgesia, i.e., enhancement of typical pain symptoms from both districts. Visceral pain, headache and musculoskeletal pains (myofascial pain from trigger points, joint pain) can enhance pain and hyperalgesia from fibromyalgia. Myofascial pain from trigger points can perpetuate pain symptoms from visceral pain conditions and trigger migraine attacks when located in the referred pain area from an internal organ or in cervico-facial areas, respectively. The pathophysiology of these pain associations is complex and probably multifactorial; among the possible processes underlying the mutual influence of symptoms recorded in the associations is modulation of central sensitization phenomena by nociceptive inputs from one or the other condition. A strong message in these pain syndrome co-occurrence is that effective treatment of one of the conditions can also improve symptoms from the other, thus suggesting a systematic and thorough evaluation of the pain patient for a global effective management of his/her suffering.
 ...
PMID:Co-occurrence of pain syndromes. 3178 21

Mast cells are tissue-resident immune cells that are involved in inflammation and fibrosis but also serve beneficial roles, including tissue maintenance, angiogenesis, pathogen clearance, and immunoregulation. Their multifaceted response and the ability of their mediators to target multiple organs and tissues means that mast cells play important roles in numerous conditions, including asthma, atopic dermatitis, drug sensitivities, ischemic heart disease, Alzheimer disease, arthritis, irritable bowel syndrome, infections (parasites, bacteria and viruses), and cancer. As a result, mast cells have become an important target for drug discovery and diagnostic research. Recent work has focused on applying novel nanotechnologies to explore cell biology. In this brief review, we will highlight the use of nanomaterials to modify mast cell functions and will discuss the potential of these technologies as research tools for understanding mast cell biology.
 ...
PMID:The Possible Uses and Challenges of Nanomaterials in Mast Cell Research. 3225 70

Belladonna has diverse pharmacotherapeutic properties with a shadowy history of beauty, life, and death. Alkaloids present in belladonna have anti-inflammatory, anticholinergic, antispasmodic, mydriatic, analgesic, anticonvulsant, and antimicrobial activities, which makes it widely applicable for the treatment of various diseases. However, because of its associated toxicity, the medicinal use of belladonna is debatable. Therefore, an evidence-based systematic review was planned to elucidate the pharmacotherapeutic potential of belladonna. A comprehensive literature search was performed in PubMed, MEDLINE, the Cochrane database, Embase, and ClinicalTrials.gov using the keywords "belladonna", "belladonna and clinical trials", and "safety and efficacy of belladonna". Articles published from 1965 to 2020 showing the efficacy of belladonna in diverse clinical conditions are included. The quality of evidence was generated using the GRADE approach, and 20 studies involving 2302 patients were included for the systematic review. Our analyses suggest that belladonna treatment appears to be safe and effective in various disease conditions, including acute encephalitis syndrome, urethral stent pain, myocardial ischemia injury, airway obstructions during sleep in infants, climacteric complaints, irritable bowel syndrome, and throbbing headache. However, better understanding of the dosage and the toxicity of tropane alkaloids of belladonna could make it an efficient remedy for treating diverse medical conditions.
 ...
PMID:Dark Classics in Chemical Neuroscience: An Evidence-Based Systematic Review of Belladonna. 3266 78

There is a significant data about overlap of functional dyspepsia (FD) and irritable bowel syndrome (IBS), however mostly the data is based on the previous diagnostic criteria and do not include other pathologies. In the previous researches there were no differential statistical analysis performed for different types of FD - postprandial distress syndrome (PDS) and epigastric pain syndrome (EBS). Aim of the study - to assess potential risk factors and the prevalence of comorbid conditions associated with FD and to compare their frequency with the same in the group with no dyspeptic complaints and in patients with different types of FD - PDS and EPS. This study was conducted as a retrospective database analysis of the patients with newly set diagnosis of FD and control group. For all the cases the information on demographic (working status, family status) and lifestyle characteristics (body mass index, smoking status, and alcohol consumption), and comorbidities were collected from the medical files. We statistically analyzed the presence of risk factors, comorbidity and its frequency in the patients with FD and compared the results with control group and in the groups with different types of FD according to the generally accepted standards. This study included 158 patients with PDS, 87 patients with EBS, and 90 volunteers with no dyspeptic complaints. Smoking, alcohol consumption, and family status were not associated with the risk of FD. The presence of sleep disorders and being unemployed increased the risk of FD. The comparison of the results of the patients with different types of FD demonstrated that there were no statistical difference in risk factors for the PDS and EPS. Gastroesophageal reflux disease (GERD), IBS, chronic gastritis and / or duodenitis, anxiety, and depression occur more frequently in the group of patients with FD. No association between autoimmune thyroiditis (AIT), arterial hypertension and ischemic heart disease (IHD) was evaluated. There was no statistical difference for the frequency of GERD, chronic gastritis and / or duodenitis, anxiety, AIT, arterial hypertension, and IHD in the patients with different types of FD. However, it was evaluated that IBS and depression occur more frequently in the group of patients with PDS, than in the patients with EPS.
 ...
PMID:RISK FACTORS AND COMORBIDITY IN DIFFERENT TYPES OF FUNCTIONAL DYSPEPSIA: RETROSPECTIVE COHORT ANALYSIS. 3327 May 86